View Older Stories
-
Teleflex (TFX) sees strong mid-day gains on chatter
-
BofA Securities Upgrades Teleflex (TFX) to Neutral
-
Teleflex nominates medical tech veteran to board, accelerates share buybacks
-
Irenic calls for strategic review committee at Teleflex
-
Teleflex responds to activist investor amid $1.8 billion divestiture plan
-
Irenic criticizes Teleflex board over acquisition refusal
-
Raymond James Upgrades Teleflex (TFX) to Outperform
-
Piper Sandler: 'When Will Things Turn in Med Tech and What Names to Own Now?'
-
Teleflex (TFX) PT Raised to $147 at Needham
-
Teleflex (TFX) Declares $0.34 Quarterly Dividend; 1.2% Yield
-
Teleflex (TFX) Misses Q4 EPS by 186c; offers guidance
-
Needham Upgrades Teleflex (TFX) to Buy
-
Teleflex (TFX) PT Raised to $139 at Wells Fargo
-
Teleflex's (TFX) Monetizing Lower Growth, Margin Businesses - Citizens
-
Needham Reiterates Hold Rating on Teleflex (TFX)
-
Teleflex to sell three business units for $2.03 billion
-
Teleflex (TFX) Tops Q3 EPS by 29c ; Offers Guidance
-
Teleflex (TFX) Declares $0.34 Quarterly Dividend; 1.1% Yield
-
Teleflex launches Barrigel rectal spacer in Japan for prostate cancer
-
Teleflex (TFX) PT Raised to $135 at Mizuho
-
Teleflex (TFX) PT Raised to $135 at RBC Capital
-
Teleflex (TFX) Tops Q2 EPS by 37c ; Offers Guidance
-
Teleflex (TFX) Declares $0.34 Quarterly Dividend; 1.2% Yield
-
Teleflex (TFX) PT Lowered to $130 at RBC Capital
-
Needham Reiterates Hold Rating on Teleflex (TFX)
-
Teleflex (TFX) Completes Acquisition of BIOTRONIK’s Vascular Intervention Business
-
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX
-
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX
-
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX
-
ROSEN, A LEADING NATIONAL FIRM, Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX
-
ROSEN, TRUSTED INVESTOR RIGHTS COUNSEL, Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX
-
Teleflex (TFX) Tops Q1 EPS by 3c; lowers guidance
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
Citizens JMP Reiterates Market Perform Rating on Teleflex (TFX)
-
Teleflex (TFX) Receives FDA 510(k) Clearance of the AC3 Range Intra-Aortic Balloon Pump
-
Teleflex (TFX) Reports Preliminary Results from IDE Study on Ringer Perfusion Balloon Catheter
-
Needham Reiterates Hold Rating on Teleflex (TFX)
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
-
TFX LEGAL NOTICE: Teleflex Incorporated Investors are Notified of Pending Securities Fraud Investigation and are Urged to Contact BFA Law
-
TELEFLEX INCORPORATED (TFX) Investors are Urged to Contact BFA Law about its Ongoing Securities Fraud Investigation
-
Teleflex (TFX) PT Lowered to $149 at Truist Following 'A Big 4Q Rev Miss'
-
TFX ALERT: Teleflex Incorporated Investors are Alerted to Contact BFA Law about its Securities Fraud Investigation
-
TFX STOCK NEWS: Teleflex Incorporated Investors are Reminded to Contact BFA Law about the Pending Securities Fraud Investigation
-
Teleflex (TFX) PT Lowered to $149 at Truist Securities
-
Teleflex (TFX) PT Lowered to $175 at Mizuho
-
Raymond James Downgrades Teleflex (TFX) to Market Perform
-
Piper Sandler Downgrades Teleflex (TFX) to Neutral

